Internal Medicine, Pulmonary Disease · Anderson, IN
NPI
1396770335
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2101 Jackson St, #110
Anderson, IN, 46016
Phone (765) 643-6012
Groups this clinician bills Medicare through
Medicare paid, 2024
$145K
1,408 services
Medicare patients, 2024
366
Average age 74
Drug cost, 2024
$2.6M
5,622 prescriptions
Company payments, 2025
$228K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David C Mares was code 99214 (office e&m - established), 417 times for 231 patients. In total David C Mares billed 1,408 services in 41 codes, and Medicare paid $145K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 417 | 231 | $82.70 | $34K |
| 99291 Critical Care E&M | Facility | 378 | 89 | $152.49 | $58K |
| 99233 Hospital E&M - Subsequent | Facility | 179 | 76 | $86.14 | $15K |
| 99223 Hospital E&M - Initial | Facility | 92 | 76 | $123.37 | $11K |
| 32557 Other Organ Systems | Facility | 71 | 24 | $105.24 | $7,472 |
| 99232 Hospital E&M - Subsequent | Facility | 49 | 29 | $58.01 | $2,843 |
| 99238 Hospital Discharge Management | Facility | 45 | 40 | $59.62 | $2,683 |
| 99213 Office E&M - Established | Office | 36 | 33 | $61.54 | $2,215 |
| 99204 Office E&M - New | Office | 19 | 19 | $90.99 | $1,729 |
| 76937 Ultrasound - Nonspecific | Facility | 11 | 11 | $10.12 | $111 |
By year: 2022 $183K for 1,696 services; 2023 $163K for 1,482 services; 2024 $145K for 1,408 services.
Medicare prescription drug claims, 2024
In 2024, the drug David C Mares prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 501 prescriptions and refills. In total David C Mares wrote 5,622 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 501 | 647 | 146 | $12K |
| Azithromycin Generic | 465 | 528 | 162 | $4,324 |
| Prednisone Generic | 432 | 487 | 192 | $1,773 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 347 | 447 | 64 | $283K |
| Montelukast Sodium Generic | 283 | 633 | 70 | $2,918 |
| Cefuroxime Cefuroxime Axetil | 179 | 179 | 125 | $3,732 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 152 | 259 | 41 | $41K |
| Fluticasone Propionate Generic | 147 | 335 | 52 | $2,804 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 140 | 171 | 38 | $108K |
| Omeprazole Generic | 101 | 225 | 27 | $870 |
| Spiriva Respimat Tiotropium Bromide | 101 | 133 | 22 | $68K |
| Ipratropium Bromide Generic | 92 | 157 | 28 | $3,935 |
| Breo Ellipta Fluticasone/Vilanterol | 88 | 132 | 16 | $50K |
| Symbicort Budesonide/Formoterol Fumarate | 86 | 140 | 27 | $32K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 84 | 138 | 23 | $13K |
Brand drugs: - claims; generic drugs: 3,562 claims; opioid claims: 96.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David C Mares $228K ($228K in general payments such as food, travel and fees) from 18 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $152K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 118 | $152K |
| Grifols USA, LLC | 26 | $35K |
| Viatris Specialty LLC | 26 | $27K |
| Verona Pharma, Inc. VRNA | 13 | $11K |
| Regeneron Healthcare Solutions, Inc. REGN | 5 | $2,226 |
| Insmed, Inc. INSM | 11 | $308 |
| GlaxoSmithKline, LLC. GSK | 16 | $248 |
| Genzyme Corporation SNY | 3 | $68.36 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $47.5 |
| Amgen Inc. AMGN | 2 | $44.54 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.